awmsg logo



blinatumomab (Blincyto®)


Reference No. 589

Publication date:
27/07/2016


Appraisal information

blinatumomab (Blincyto®) 38.5 microgram/vial powder for concentrate and solution for solution for infusion


Company: Amgen Ltd
BNF category: Malignant disease and immunosupression
NMG meeting date: 08/06/2016
AWMSG meeting date: 13/07/2016
   
   
Submission Type: Full Submission
Status: Superseded
Advice No: 1916
Ministerial ratification: 26/07/2016

Current Progress


Submission
received
NMG
meeting
AWMSG
meeting
Ministerial
Ratification

AWMSG advice

AWMSG ADVICE SUPERSEDED BY NICE GUIDANCE (TA450) NICE GUIDANCE ISSUED JUNE 2017 (Refer to NICE website for full guidance on NICE recommendations, including any specific restrictions on the use of the technology)
Final Appraisal Recommendation (FAR)
Download
AWMSG Secretariat Appraisal Report (ASAR)
Download
Clinical Expert (CE) Summary
Download